Brokerage firm Choice Broking has maintained a 'buy' rating on Park Medi World with a revised target price of ₹350, expecting approximately 20% upside from current levels. According to the brokerage's recent report, the management expects Park Hospitals' growth to be driven by aggressive capacity expansion, efficient capital deployment, a richer case mix, optimised ALOS, improved payor mix and revised CGHS rate benefits. The company turned debt-free in February 2026 and continues to generate healthy operating cash flows, providing financial flexibility for expansion.
Park Medi World reported robust Q4 FY26 results on Tuesday, 12 May, with consolidated net profit attributable to owners rising 58% year-on-year to ₹70.9 crore, compared to ₹44.8 crore in the same quarter last year. The company's consolidated net profit after tax increased 47% YoY to ₹76.8 crore, up from ₹52.4 crore in the previous year. Revenue from operations grew 30% YoY to ₹460.4 crore, expanding from ₹353.9 crore, while EBITDA increased 44% YoY to ₹127.4 crore with margins expanding to 27.7% from 25.0%, indicating better cost efficiencies and operating leverage.
The company witnessed significant growth during the year, achieving a 20% boost in capacity by adding 610 beds through acquisitions in Bhatinda (250 beds) and Agra (360 beds), bringing the total capacity to 3,610 beds as of 31 March 2026. According to the exchange filing, the management revealed that by the second year, revenues are expected to scale up to ₹1,400 million (40% YoY growth), with EBITDA improving to ₹35 million (25% margin) and PAT of ₹21 million (15% margin), supported by occupancy rising to 70–75%.
The healthcare stock has delivered almost multibagger returns of 90% on a year-to-date basis, with the share price trend remaining positive by surging 11% in a week and 20.50% in a month. Park Medi World share price, which made its debut at ₹158.80 apiece in December 2025, is currently trading at ₹285.19 apiece on NSE, representing an 80% premium above the listing price. On Wednesday, the stock was trading marginally lower at ₹285.19 apiece on NSE.
